Gemcitabin

DRUG7 trials

Sponsors

Spanish Lung Cancer Group, Beijing Tongren Hospital, German Cancer Research Center, Crescent Biopharma, Inc., Peking University

Conditions

Advanced Stage or Metastatic Pancreatic Ductal AdenocarcinomaBCG-Unresponsive Bladder CancerBiliary Tract Cancer (BTC)CYP3A InhibitorExtranodal NK/T-cell Lymphoma, Nasal TypeLocally Advanced / Metastatic Solid TumorsNon-Muscle-Invasive Bladder CancerNon-Small Cell Lung Cancer

Phase 1

A Trial of Cobicistat and Gemcitabine and Nab-Paclitaxel in Patients with Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma

TerminatedNCT05494866

German Cancer Research CenterAdvanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma, CYP3A Inhibitor, Pancreatic Adenocarcinoma +2

Start: 2022-12-07End: 2024-03-15Updated: 2025-03-25

CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

RecruitingNCT07335497

Crescent Biopharma, Inc.Locally Advanced / Metastatic Solid Tumors

Start: 2026-02-17End: 2029-02-01Target: 540Updated: 2026-10-20

Phase 2

GPED Regimen for Relapsed/Refractory or Advanced ENKTCL

Beijing Tongren HospitalExtranodal NK/T-cell Lymphoma, Nasal Type

Start: 2020-03-21End: 2023-04-30Target: 29Updated: 2020-05-28

Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma

Active, not recruitingNCT07480850

Cancer Institute and Hospital, Chinese Academy of Medical SciencesRefractory Diffuse Large B-Cell Lymphoma (DLBCL)

Start: 2026-01-01End: 2028-01-02Target: 40Updated: 2026-03-18

Sequential Gemcitabine Plus Docetaxel Versus Gemcitabine Plus Mitomycin C for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer

RecruitingNCT07747740

Blokhin's Russian Cancer Research CenterBCG-Unresponsive Bladder Cancer, Non-Muscle-Invasive Bladder Cancer

Start: 2026-07-09End: 2030-12-30Target: 228Updated: 2026-08-05

Phase 3

Phase III Study (Tarceva®) vs Chemotherapy to Treat Advanced Non-Small Cell Lung Cancer in Patients With Mutations in the TK Domain of EGFR

CompletedNCT00446225

Spanish Lung Cancer GroupNon-Small Cell Lung Cancer

Start: 2007-02-15End: 2012-12-31Updated: 2025-03-05

Unknown Phase

HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer

RecruitingNCT07466238

Peking UniversityBiliary Tract Cancer (BTC)

Start: 2026-03-31End: 2029-03-31Target: 40Updated: 2026-05-08

Related Papers

ASCEND: A phase 1/2, dose-escalation, optimization, and dose-expansion study to evaluate the safety and antitumor activity of CR-001 in adults with locally advanced or metastatic solid tumors.

Journal of Clinical Oncology2026-05-28

Abstract CT186: Pulmonary toxicity associated with increased 6-OH-paclitaxel exposure in pancreatic cancer patients treated with nab-paclitaxel, gemcitabine and cobicistat: Results of the IntenSify trial

Cancer Research2026-04-17

Protocol of the <scp>IntenSify‐Trial</scp>: An open‐label phase I trial of the <scp>CYP3A</scp> inhibitor cobicistat and the cytostatics gemcitabine and nab‐paclitaxel in patients with advanced stage or metastatic pancreatic ductal adenocarcinoma to evaluate the combination's pharmacokinetics, safety, and efficacy

Clinical and Translational Science2023-11-035 citations

AB036. Comparison of the effectiveness of gefitinib, erlotinib and afatinib in epidermal growth factor receptor mutated tumors of non-small cell lung cancer

Annals of Translational Medicine2016-11-01

Association of<i>EGFR</i>L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial

JAMA Oncology2015-02-26234 citations

ROR1 as a novel therapeutic target for EGFR-mutant non-small-cell lung cancer patients with the EGFR T790M mutation.

2014-06-0126 citations

The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial.

2014-02-03193 citations

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

2012-01-264247 citations